Trikafta safely improved lung function and reduced exacerbations in people with cystic fibrosis (CF) who started treatment after…
Articles by Andrea Lobo, PhD
Treatment with Alyftrek, a combination of vanzacaftor, tezacaftor, and deutivacaftor, led to better patient-reported health-related quality of life for…
An independent data monitoring committee, following a safety review, recommended that a Phase 2 trial of BX004, Biomx’s experimental…
The U.S. Food and Drug Administration (FDA) has cleared the start of the third part of a Phase 2 clinical…
Researchers have identified three groups of symptoms with interconnected severity — respiratory-energy, mood-gastrointestinal irritability, and pain-gastrointestinal abnormal motility — in…
All eligible cystic fibrosis (CF) patients in England can now receive Vertex Pharmaceuticals’ CF treatment Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), after…
More than a third of caregivers of children with cystic fibrosis (CF) reported delays in getting information about the…
The Cystic Fibrosis Foundation (CFF) has awarded $5 million to the Cleveland Clinic to continue as the biorepository coordinating…
The Clairity Ball — the hallmark annual event of Claire’s Place Foundation — is set to return to…
The events slated for this year’s Cystic Fibrosis Awareness Month aim to celebrate the accomplishments, milestones, and hopes of those…